Search

REGENXBIO Inc

Открыт

СекторЗдравоохранение

8.9 10.56

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

7.73

Макс.

8.66

Ключевые показатели

By Trading Economics

Доход

113M

23M

Продажи

102M

108M

Прибыль на акцию

0.43

Рентабельность продаж

21.023

Сотрудники

371

EBITDA

112M

34M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+175.68% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

128M

748M

Предыдущая цена открытия

-1.66

Предыдущая цена закрытия

8.9

Новостные настроения

By Acuity

58%

42%

291 / 340 Рейтинг в Healthcare

REGENXBIO Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 авг. 2026 г., 19:51 UTC

News
Social Media
Event

Regenxbio Inc shares are lower following the FDA's clinical hold on RGX-121 due to MRI findings, with Bank of America maintaining a $15 price target.

21 авг. 2026 г., 19:26 UTC

Regenxbio Inc shares are declining today amid notable volatility, pulling back significantly from an earlier peak during the session. No specific news was identified.

20 авг. 2026 г., 20:02 UTC

Regenxbio Inc. shares are lower as biotechnology stocks face pressure today, with no specific news identified to explain the decline.

19 авг. 2026 г., 22:06 UTC

Regenxbio Inc shares are higher in after-market trading, continuing a positive trend since Wednesday's close and remaining above their 20-day moving average.

18 авг. 2026 г., 19:46 UTC

Regenxbio Inc's shares are lower today amid rising Treasury yields and inflation concerns. The stock remains above its 20-day moving average.

17 авг. 2026 г., 20:06 UTC

Regenxbio Inc shares are higher today, reflecting strong market performance. The stock remains near its one-month high and above its 20-day moving average.

14 авг. 2026 г., 19:36 UTC

Regenxbio Inc shares are higher during Friday's session, advancing despite a reported decline in retail sales for July.

13 авг. 2026 г., 21:31 UTC

Regenxbio Inc shares are lower in after-market hours, pulling back from an earlier session high. No specific news was identified to explain the decline.

12 авг. 2026 г., 19:41 UTC

Regenxbio Inc shares are higher today amid positive market sentiment following a modest increase in the core Consumer Price Index.

11 авг. 2026 г., 19:11 UTC

Biotechnology stocks are advancing today, contributing to Regenxbio Inc's higher price movement. The stock pulled back earlier but remains in positive territory overall.

10 авг. 2026 г., 19:46 UTC

News

Regenxbio Inc shares are lower today after H.C. Wainwright cut its price target to $23.00, despite a strong Q2 earnings report.

7 авг. 2026 г., 20:06 UTC

News

Barclays downgraded Regenxbio Inc to Equal-Weight from Overweight, maintaining a $12 price target. Shares are trading lower amid concerns about growth prospects.

6 авг. 2026 г., 23:31 UTC

News

Regenxbio Inc shares are higher in after-market hours following key milestones in its Q2 2026 earnings call, including FDA alignment for RGX-202's development.

5 авг. 2026 г., 19:26 UTC

Regenxbio Inc shares are higher during Wednesday's session, despite intraday volatility. Broader market sentiment is influenced by a recent decline in crude oil prices.

4 авг. 2026 г., 19:56 UTC

Regenxbio Inc shares are higher, reflecting market strength amid a decline in crude oil prices that eased inflation concerns. No specific company news was identified.

31 июл. 2026 г., 19:36 UTC

Regenxbio Inc shares are lower, influenced by declines in the Biotechnology sector. The stock showed volatility, briefly rising earlier in the session.

30 июл. 2026 г., 19:29 UTC

Regenxbio Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday. The stock remains below its 20-day moving average.

29 июл. 2026 г., 19:56 UTC

Macro Event

Regenxbio Inc is trading higher as the Federal Reserve maintains interest rates, reflecting heightened market sensitivity amid ongoing economic growth and geopolitical tensions.

28 июл. 2026 г., 18:16 UTC

Regenxbio Inc shares are lower, continuing a three-day decline amid broader market pressures, including losses in Asian markets like the Nikkei 225 Index.

27 июл. 2026 г., 19:36 UTC

Regenxbio Inc is trading higher during Monday's session, recovering from earlier declines. Broader market sentiment is influenced by a significant drop in oil prices.

24 июл. 2026 г., 20:07 UTC

Regenxbio Inc shares are lower today, continuing a decline since Thursday's close. The stock remains below its 20-day moving average, indicating market weakness.

22 июл. 2026 г., 18:26 UTC

Regenxbio Inc shares are lower amid geopolitical tensions and rising crude oil prices. Earlier in the session, shares briefly recovered but have since declined.

21 июл. 2026 г., 19:31 UTC

Regenxbio Inc is higher during Tuesday's session, tracking the broader market's gains amid positive sentiment from recent earnings reports. No specific company news was identified.

20 июл. 2026 г., 19:31 UTC

Event
News
Social Media

Regenxbio shares rise after positive long-term trial results for surabgene lomparvovec, showing sustained vision improvements in patients with retinal conditions.

Сравнение c конкурентами

Изменение цены

REGENXBIO Inc Прогноз

Целевая цена

By TipRanks

175.68% рост

Прогноз на 12 месяцев

Средняя 22.22 USD  175.68%

Максимум 42 USD

Минимум 10 USD

Основано на мнении 9 аналитиков Wall Street, спрогнозировавших целевые цены для REGENXBIO Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

9 ratings

7

Покупка

2

Удержание

0

Продажа

Настроения

By Acuity

291 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
help-icon Live chat